Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment

https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00090-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-8744gwmCLfBdyyYUAG8tZzz9i0A08rjWDY_tLP2jmeuoOvdBazb6layD8sDwVlKLBUQL-odKmgtMim2PVxR7YtEYxVEA&_hsmi=315814605&utm_content=315331689&utm_source=hs_email